KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Shares Outstanding (2016 - 2025)

Inovio Pharmaceuticals' Shares Outstanding history spans 16 years, with the latest figure at $53.6 million for Q3 2025.

  • For Q3 2025, Shares Outstanding rose 595240733.33% year-over-year to $53.6 million; the TTM value through Sep 2025 reached $53.6 million, up 595240733.33%, while the annual FY2024 figure was $9.0, 100.0% down from the prior year.
  • Shares Outstanding for Q3 2025 was $53.6 million at Inovio Pharmaceuticals, up from $36.7 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $249.5 million in Q3 2022 and bottomed at $9.0 in Q1 2021.
  • The 5-year median for Shares Outstanding is $21.1 million (2022), against an average of $37.8 million.
  • The largest annual shift saw Shares Outstanding surged 2772058388.89% in 2022 before it tumbled 100.0% in 2023.
  • A 5-year view of Shares Outstanding shows it stood at $9.0 in 2021, then changed by 0.0% to $9.0 in 2022, then skyrocketed by 253256288.89% to $22.8 million in 2023, then crashed by 100.0% to $9.0 in 2024, then soared by 595240733.33% to $53.6 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Shares Outstanding are $53.6 million (Q3 2025), $36.7 million (Q2 2025), and $9.0 (Q1 2025).